
亚太地区 miRNA 测序和分析市场预测至 2027 年 - COVID-19 影响和区域分析(按产品(文库制备和耗材)、技术(合成测序、纳米孔和离子半导体测序)和最终用户(研究所、学术界)和 CRO)
No. of Pages: 117 | Report Code: TIPRE00022186 | Category: Life Sciences
No. of Pages: 117 | Report Code: TIPRE00022186 | Category: Life Sciences
miRNA是一种20-30个核苷酸的小非编码RNA分子,在基因调控中发挥着重要作用。 miRNA 与信使 RNA (mRNA) 部分互补,其主要功能是下调基因表达。自从它们被发现以来,它们已成为重要细胞功能的重要调节者。 miRNA 与病毒感染、自身免疫性疾病和癌变等病理过程相关。
MicroRNA (miRNA) 参与分化过程,它们充当细胞类型识别的标记。 miRNA 与病毒感染、自身免疫性疾病和癌变等病理过程相关。因此,人们正在进行广泛的研究来鉴定新的 miRNA。此外,关于 miRNA 在疾病发展中的作用的新发现使其成为新型治疗方法的关键目标。几种针对癌症和肝炎等疾病的 miRNA 靶向疗法已进入临床阶段。例如,Santaris Pharma 开发了一种名为 Miravirsen 的治疗分子,靶向 miR-122,用于治疗丙型肝炎病毒(HCV)感染;该分子正处于 II 期临床试验中。因此,用于识别诊断和治疗疾病的新分子的基因组研究资金的增加以及随之而来的 miRNA 应用范围的扩大正在推动亚太地区 miRNA 测序和检测市场的增长。
COVID-19 大流行正在严重影响亚太地区国家。由于各国对货物和人员运输的限制而导致供应链中断,以及对治疗 COVID-19 的有效疗法的巨大需求,使该地区的医疗保健研究行业陷入危急境地。此外,随着人们对 miRNA 测序和检测在 COVID-19 诊断中的重要性的认识不断提高,也推动了对 miRNA 测序和检测产品的需求。许多国际市场参与者正在努力扩展其在亚太地区的业务,以利用该地区所展现的巨大商业潜力。例如,新加坡 MiRXES 通过在日本设立新子公司扩大了其在亚太地区的业务。因此,持续的疫情正在促进亚太地区 miRNA 测序和检测市场的增长。
亚太地区 miRNA 测序和检测市场按产品细分为文库制备和耗材。耗材细分市场在 2019 年占据了更大的市场份额,而文库制备细分市场预计在预测期内将实现更高的复合年增长率。
基于技术亚太地区 miRNA 测序和检测市场分为合成测序、纳米孔测序和离子半导体测序。合成测序领域在 2019 年占据了最大的市场份额;然而,纳米孔细分市场预计在 2020 年至 2027 年期间将实现最高的复合年增长率。
根据最终用户,亚太 miRNA 测序和检测市场细分为研究机构、学术界和 CRO。研究机构细分市场在 2019 年占据了最大的市场份额,预计在此期间的市场复合年增长率最高。
Strategic insights for Asia Pacific miRNA Sequencing and Assay involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
Report Attribute | Details |
---|---|
Market size in 2019 | US$ 40.65 Million |
Market Size by 2027 | US$ 104.82 Million |
Global CAGR (2020 - 2027) | 12.7% |
Historical Data | 2017-2018 |
Forecast period | 2020-2027 |
Segments Covered |
By 产品
|
Regions and Countries Covered | 亚太地区
|
Market leaders and key company profiles |
The regional scope of Asia Pacific miRNA Sequencing and Assay refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The Asia Pacific miRNA Sequencing and Assay Market is valued at US$ 40.65 Million in 2019, it is projected to reach US$ 104.82 Million by 2027.
As per our report Asia Pacific miRNA Sequencing and Assay Market, the market size is valued at US$ 40.65 Million in 2019, projecting it to reach US$ 104.82 Million by 2027. This translates to a CAGR of approximately 12.7% during the forecast period.
The Asia Pacific miRNA Sequencing and Assay Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific miRNA Sequencing and Assay Market report:
The Asia Pacific miRNA Sequencing and Assay Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific miRNA Sequencing and Assay Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific miRNA Sequencing and Assay Market value chain can benefit from the information contained in a comprehensive market report.